SNK01

PreclinicalBiologic

NNKGen Biotech, Inc.

SNK01 is one of 48 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Alzheimer's DiseaseRecruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Alzheimer's DiseasePreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Imjudo

AstraZeneca

Preclinical

5 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vidaza

1 9

Treatment

GSK

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Alzheimer's Disease

NCT06189963

Q2 2028

Phase 2Recruiting

Study completion

NCT07228078

Clinical

Trials by Indication[1]

Alzheimer's Disease2 trials

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Terminated·NNKGen Biotech, Inc.·Phase 1·NCT04678453·10 enrolled

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Recruiting·NNKGen Biotech, Inc.·Preclinical·NCT06189963·36 enrolled

Non-Small Cell Lung Cancer1 trial

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Unknown status·NNKMAX Co., Ltd.·Phase 1/2·NCT04872634·24 enrolled

Unresectable Cancer1 trial

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Completed·NNKGen Biotech, Inc.·Phase 1·NCT03941262·27 enrolled

Metastatic1 trial

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Terminated·NNKGen Biotech, Inc.·Phase 1/2·NCT05099549·11 enrolled

Efficacy1 trial

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Withdrawn·NNKGen Biotech, Inc.·Phase 1/2·NCT04464967

1 more indication

Unspecified1 trial

Open-Label Extension Protocol to SNK01-AD01 Study

Recruiting·NNKGen Biotech, Inc.·Phase 2·NCT07228078·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SNK01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNK01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNK01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NKGen Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: NNKGen Biotech, Inc.

SNK01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Alzheimer's Disease2 trials

Non-Small Cell Lung Cancer1 trial

Unresectable Cancer1 trial

Metastatic1 trial

Efficacy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News